Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Tvardi Therapeutics, Inc. - Common Stock (NQ:TVRD)

4.510 -0.460 (-9.26%)
Streaming Delayed Price Updated: 1:01 PM EDT, Oct 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Tvardi Therapeutics, Inc. - Common Stock

Unusual volume stocks in Monday's session
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
In today's session, these stocks are experiencing unusual volume.
Unusual volume stocks are being observed in Thursday's session. 
Via Chartmill
Unusual volume stocks in Wednesday's session
Which stocks have an unusual volume on Wednesday? 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Tvardi Therapeutics' Lung Disease Candidate Fails To Show Any Clinical Benefit, Stock Sinks
Tvardi Therapeutics stock falls as Phase 2 IPF trial of TTI-101 shows no significant FVC improvement, with high variability and placebo response. 
Via Benzinga
Gold Rises Over 3%; Tvardi Therapeutics Shares Plunge
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Dow Surges 1%; Fastenal Shares Fall After Q3 Results
 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why Did Tvardi Therapeutics Stock Plummet 87% Pre-Market Today?
The company said that its investigational drug did not meet its goal in a study, and no statistically significant differences between placebo and treatment arms were observed after preliminary review... 
Via Stocktwits
Tvardi Posts Q2 Net Income Turnaround
Via The Motley Fool
Topics Intellectual Property
Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside
Tvardi advances fibrosis drug TTI-101 in IPF and liver cancer as Piper initiates with $78 target; merger boosts cash runway into late 2026. 
Via Benzinga
This Modine Manufacturing Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Why Coursera Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.